Prestige Consumer Healthcare Inc. Stock price

Equities

PBH

US74112D1019

Pharmaceuticals

Market Closed - Nyse 04:00:01 2023-12-01 pm EST Intraday chart for Prestige Consumer Healthcare Inc. 5-day change 1st Jan Change
58.61 USD +2.20% +0.50% -6.37%
Sales 2024 * 1,136 M Sales 2025 * 1,162 M Capitalization 2,908 M
Net income 2024 * 216 M Net income 2025 * 230 M EV / Sales 2024 *
2,56x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 *
2,50x
P/E ratio 2024 *
13,6x
P/E ratio 2025 *
12,7x
Employees 560
Yield 2024 *
-
Yield 2025 *
-
Free-Float 88.64%
More Fundamentals * Assessed data
Dynamic Chart
Prestige Consumer Healthcare Unit Recalls 2 Lots of Antifungal Spray Powder Due to High Levels of Benzene MT
Transcript : Prestige Consumer Healthcare Inc., Q2 2024 Earnings Call, Nov 02, 2023 CI
Prestige Consumer Healthcare Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Earnings Flash (PBH) PRESTIGE CONSUMER HEALTHCARE Posts Q2 Revenue $286.3M, vs. Street Est of $285.2M MT
Earnings Flash (PBH) PRESTIGE CONSUMER HEALTHCARE Reports Q2 EPS $1.07, vs. Street Est of $1.07 MT
Prestige Consumer Healthcare Inc. Reaffirms Earnings Guidance for the Fiscal Year 2024 CI
Prestige Consumer Healthcare Insider Sold Shares Worth $149,657, According to a Recent SEC Filing MT
Transcript : Prestige Consumer Healthcare Inc. Presents at Barclays Global Consumer Staples Conference 2023, Sep-07-2023 03:00 PM CI
Insider Sell: Prestige Consumer Healthcare MT
Transcript : Prestige Consumer Healthcare Inc., Q1 2024 Earnings Call, Aug 03, 2023 CI
Prestige Consumer Healthcare Fiscal Q1 Earnings Fall, Revenue Rises; Fiscal-Year 2024 Outlook Reaffirmed MT
Tranche Update on Prestige Consumer Healthcare Inc.'s Equity Buyback Plan announced on May 4, 2023. CI
Earnings Flash (PBH) PRESTIGE CONSUMER HEALTHCARE Reports Q1 Revenue $279.3M, vs. Street Est of $278.4M MT
Earnings Flash (PBH) PRESTIGE CONSUMER HEALTHCARE Reports Q1 EPS $1.06, vs. Street Est of $1.01 MT
Prestige Consumer Healthcare Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
More news
1 day+2.20%
1 week+0.50%
Current month+2.20%
1 month-1.60%
3 months+0.41%
6 months+0.19%
Current year-6.37%
More quotes
1 week
56.61
Extreme 56.61
58.75
1 month
56.61
Extreme 56.61
60.32
Current year
52.90
Extreme 52.9
68.54
1 year
52.90
Extreme 52.9
68.54
3 years
34.26
Extreme 34.26
68.54
5 years
26.25
Extreme 26.25
68.54
10 years
24.94
Extreme 24.94
68.54
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 2010
Director of Finance/CFO 48 2016
Chief Operating Officer 62 2018
Members of the board TitleAgeSince
Director/Board Member 67 2015
Director/Board Member 70 2021
Director/Board Member 58 2020
More insiders
Date Price Change Volume
23-12-01 58.61 +2.20% 243,418
23-11-30 57.35 +0.61% 205,699
23-11-29 57.00 -0.23% 183,438
23-11-28 57.13 -1.58% 151,565
23-11-27 58.05 -0.46% 162,622

Delayed Quote Nyse, December 01, 2023 at 04:00 pm EST

More quotes
Prestige Consumer Healthcare Inc. is engaged in the development, manufacturing, marketing, sales and distribution of over-the-counter (OTC) health and personal care products to mass merchandisers, drug, food, dollar, convenience, club and e-commerce stores in North America (the United States and Canada) and in Australia and certain other international markets. The Company operates through two segments: North American OTC Healthcare and International OTC Healthcare. Its diverse portfolio of brands include Monistat and Summer's Eve women's health products, BC and Goody's pain relievers, Clear Eyes and TheraTears eye care products, DenTek specialty oral care products, Dramamine motion sickness treatments, Fleet enemas and glycerin suppositories, Chloraseptic and Luden's sore throat treatments and drops, Compound W wart treatments, Little Remedies pediatric over-the-counter products, Boudreaux's Butt Paste diaper rash ointments, Nix lice treatment, Debrox earwax remover, and others.
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
58.61USD
Average target price
71.50USD
Spread / Average Target
+21.99%
Consensus
1st Jan change Capi.
-6.37% 2 908 M $
+59.64% 525 B $
-10.34% 381 B $
-6.75% 262 B $
-11.26% 253 B $
-17.52% 221 B $
+2.14% 202 B $
-9.09% 200 B $
-43.58% 163 B $
+3.74% 146 B $
Other Pharmaceuticals
  1. Stock
  2. Equities
  3. Stock Prestige Consumer Healthcare Inc. - Nyse
Secure and Increase the Performance of your Investments with our Team of Experts at your Side
Securing my Investments
fermer